默克公司周三表示，其实验性药物显著减少了慢性皮肤病患者皮肤的炎症性病变，达到了中期研究的主要目标。
Merck said on Wednesday its experimental drug significantly reduced inflammatory skin lesions in patients with a chronic skin disease, meeting the main goal of a mid-stage study.
路透社
默克实验性皮肤病药物在中期研究中取得成功Merck's experimental skin disease drug succeeds in mid-stage study
点「原文对照」整页切到原文，或双击某段只看那段的原文。